Duopharma Biotech Berhad

Kuala Lumpur Stock Exchange 7148.KL

Duopharma Biotech Berhad Price to Earnings Ratio (P/E) on January 14, 2025: 23.06

Duopharma Biotech Berhad Price to Earnings Ratio (P/E) is 23.06 on January 14, 2025, a 0.32% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Duopharma Biotech Berhad 52-week high Price to Earnings Ratio (P/E) is 28.33 on September 26, 2024, which is 22.85% above the current Price to Earnings Ratio (P/E).
  • Duopharma Biotech Berhad 52-week low Price to Earnings Ratio (P/E) is 19.95 on April 17, 2024, which is -13.50% below the current Price to Earnings Ratio (P/E).
  • Duopharma Biotech Berhad average Price to Earnings Ratio (P/E) for the last 52 weeks is 22.84.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Kuala Lumpur Stock Exchange: 7148.KL

Duopharma Biotech Berhad

CEO Mr. Wan Amir-Jeffery Bin Wan Abdul Majid
IPO Date July 19, 2002
Location Malaysia
Headquarters CIMB HUB
Employees 1,650
Sector Health Care
Industries
Description

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.

Similar companies

7106.KL

Supermax Corporation Berhad

USD 0.25

-1.78%

7153.KL

Kossan Rubber Industries Bhd

USD 0.54

-0.45%

7113.KL

Top Glove Corporation Bhd.

USD 0.27

-0.87%

5168.KL

Hartalega Holdings Berhad

USD 0.80

-0.04%

StockViz Staff

January 15, 2025

Any question? Send us an email